Value of Epidermal Growth Factor Receptor Status Compared with Growth Fraction and Other Factors for Prognosis in Early Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1992 Nov 1

PMID 1419645

Citations 14

Authors

G Gasparini

P Bevilacqua

F Pozza

S Meli

P Boracchi

E Marubini

J R Sainsbury

Affiliations

Soon will be listed here.

Abstract

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein whose expression is important in the regulation of breast cancer cell growth. The relationship between EGFR status (determined by an immunocytochemical assay) and various prognostic factors was investigated in 164 primary breast cancers. Overall 56% of tumours were EGFR-positive and the expression of EGFR was unrelated to axillary node status, tumour size and histological grade; and it was poorly associated with the tumour proliferative activity measured by Ki-67 immuno-cytochemistry. The relapse-free survival (RFS) probability at 3-years was significantly worse for patients with EGFR positive tumours (P = 0.003) and for those whose Ki-67 score was > 7.5% (P = 0.0027), as well as in patients with axillary node involvement (P = 0.01) and with poorly differentiated tumours (P = 0.04). Immunocytochemical determination of EGFR and cell kinetics gave superimposable prognostic information for predicting RFS with odds ratios of 3.51, when evaluated singly. In our series of patients EGFR, Ki-67 and node status retain their prognostic value concerning RFS in multivariate analysis. The 3-year probability of overall survival (OS) was significantly better in node-negative patients (P = 0.04) and was similar in EGFR-positive and negative patients. In conclusion, EGFR status appears to be a significant and independent indicator of recurrence in human breast cancer and the concomitant measurement of the tumour proliferative activity seems to improve the selection of patients with different risks of recurrence.

Citing Articles

High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

Abubakar M, Howat W, Daley F, Zabaglo L, McDuffus L, Blows F J Pathol Clin Res. 2016; 2(3):138-53.

PMID: 27499923 PMC: 4958735. DOI: 10.1002/cjp2.42.

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Luporsi E, Andre F, Spyratos F, Martin P, Jacquemier J, Penault-Llorca F Breast Cancer Res Treat. 2011; 132(3):895-915.

PMID: 22048814 PMC: 3332349. DOI: 10.1007/s10549-011-1837-z.

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

de Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano M, Durbecq V Br J Cancer. 2007; 96(10):1504-13.

PMID: 17453008 PMC: 2359936. DOI: 10.1038/sj.bjc.6603756.

The epidermal growth factor receptor in breast cancer.

Fox S, Harris A J Mammary Gland Biol Neoplasia. 1997; 2(2):131-41.

PMID: 10882299 DOI: 10.1023/a:1026399613946.

Prospective evaluation of prognostic factors in operable breast cancer.

Hawkins R, Tesdale A, Killen M, Jack W, Chetty U, Dixon J Br J Cancer. 1996; 74(9):1469-78.

PMID: 8912547 PMC: 2074769. DOI: 10.1038/bjc.1996.567.

References

Silvestrini R, Daidone M, Gasparini G . Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer. 1985; 56(8):1982-7. DOI: 10.1002/1097-0142(19851015)56:8<1982::aid-cncr2820560816>3.0.co;2-i. View

TUBIANA M, Pejovic M, Chavaudra N, Contesso G, Malaise E . The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer. 1984; 33(4):441-5. DOI: 10.1002/ijc.2910330404. View

Toi M, Osaki A, Yamada H, Toge T . Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer. 1991; 27(8):977-80. DOI: 10.1016/0277-5379(91)90262-c. View

Koenders P, Beex L, Geurts-Moespot A, Heuvel J, Kienhuis C, BENRAAD T . Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991; 51(17):4544-8. View

Bonadonna G . Adjuvant chemotherapy in node-negative breast cancer. NCI consensus conference. Eur J Cancer. 1990; 26(7):844-5. DOI: 10.1016/0277-5379(90)90168-s. View

Isola J, Helin H, Helle M, Kallioniemi O . Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990; 65(5):1180-4. DOI: 10.1002/1097-0142(19900301)65:5<1180::aid-cncr2820650525>3.0.co;2-7. View

Foekens J, Portengen H, van Putten W, Trapman A, Reubi J, Klijn J . Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989; 49(24 Pt 1):7002-9. View

Kalofonos H, Pawlikowska T, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D . Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med. 1989; 30(10):1636-45. View

Neal D, Marsh C, Bennett M, Abel P, Hall R, Sainsbury J . Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985; 1(8425):366-8. DOI: 10.1016/s0140-6736(85)91386-8. View

10.

Pekonen F, Partanen S, Makinen T, Rutanen E . Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 1988; 48(5):1343-7. View

11.

Lippman M, Dickson R, Bates S, Knabbe C, Huff K, Swain S . 8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat. 1986; 7(2):59-70. DOI: 10.1007/BF01806790. View

12.

Freeman J, BUSCH R, Gyorkey F, Gyorkey P, Ross B, Busch H . Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. Cancer Res. 1988; 48(5):1244-51. View

13.

McGuire W . Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987; 10(1):5-9. DOI: 10.1007/BF01806129. View

14.

Fisher B, RAVDIN R, AUSMAN R, Slack N, Moore G, NOER R . Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968; 168(3):337-56. PMC: 1387335. DOI: 10.1097/00000658-196809000-00004. View

15.

Hsu S, RAINE L, FANGER H . A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981; 75(5):734-8. DOI: 10.1093/ajcp/75.5.734. View

16.

Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, STEIN H . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133(4):1710-5. View

17.

Heldin C, Westermark B . Growth factors: mechanism of action and relation to oncogenes. Cell. 1984; 37(1):9-20. DOI: 10.1016/0092-8674(84)90296-4. View

18.

BLOOM H, Richardson W . Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3):359-77. PMC: 2073885. DOI: 10.1038/bjc.1957.43. View

19.

Dexter D, Kowalski H, Blazar B, Fligiel Z, Vogel R, Heppner G . Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978; 38(10):3174-81. View

20.

Gasparini G, Reitano M, Bevilacqua P, Meli S, Pozza F, Santini G . Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas. Anticancer Res. 1991; 11(4):1597-603. View